Rob Chess

The Artisan team is passionate about crafting customized cell engineering solutions to solve the most challenging problems in human health applications. With facilities in Denver, Colorado and Toronto, Ontario, Artisan is building a foundry for CRISPR-driven cell therapy engineering.

BigHat’s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics. Our AI-enabled experimental platform integrates a high-speed characterization or “wet” lab with machine learning technologies to speed the antibody engineering process. When applied, these design capabilities have the potential to drive the development of new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases. BigHat is backed by Section 32, ‍Andreessen Horowitz, 8VC, Amgen Ventures, Bristol Myers Squibb, Quadrille, Grids Capital, AME Cloud Ventures, Innovation Endeavors and Gaingels.

Biota is commercializing Biosurveillance for energy and industrial customers. We unlock the use of ever present microbes as sensors and tracers. Through our Biosurveillance Platform, Biota is able to extract this valuable data source, digitize it, and fill critical data gaps that other data sources are unable to provide. Our Biosurveillance Platform provides a non invasive, cost effective, 4D diagnostic that characterizes industrial environments and tracks the movement of both surface and subsurface fluids. Current and emerging applications cover energy, decarbonization, environmental monitoring, as well as industrial asset integrity.

The Artisan team is passionate about crafting customized cell engineering solutions to solve the most challenging problems in human health applications. With facilities in Denver, Colorado and Toronto, Ontario, Artisan is building a foundry for CRISPR-driven cell therapy engineering.

BigHat’s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics. Our AI-enabled experimental platform integrates a high-speed characterization or “wet” lab with machine learning technologies to speed the antibody engineering process. When applied, these design capabilities have the potential to drive the development of new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases. BigHat is backed by Section 32, ‍Andreessen Horowitz, 8VC, Amgen Ventures, Bristol Myers Squibb, Quadrille, Grids Capital, AME Cloud Ventures, Innovation Endeavors and Gaingels.

Biota is commercializing Biosurveillance for energy and industrial customers. We unlock the use of ever present microbes as sensors and tracers. Through our Biosurveillance Platform, Biota is able to extract this valuable data source, digitize it, and fill critical data gaps that other data sources are unable to provide. Our Biosurveillance Platform provides a non invasive, cost effective, 4D diagnostic that characterizes industrial environments and tracks the movement of both surface and subsurface fluids. Current and emerging applications cover energy, decarbonization, environmental monitoring, as well as industrial asset integrity.